Pancreatic Cancer Could Become Second Deadliest by 2035, Portuguese Experts Warn

On World Pancreatic Cancer Day today, Portuguese specialists are warning that pancreatic cancer will become the second-leading cause of cancer death in Portugal and worldwide by 2035, as a national campaign runs until November 28 to break the disease’s silence, according to Dnoticias.

Around 2,191 people in Portugal receive a pancreatic cancer diagnosis each year, and 2,051 die of it — more than five deaths a day, according to dnoticias.pt, which cites GLOBOCAN 2024 estimates from the International Agency for Research on Cancer. For every 100 new cases a year, 94 people die.

Rank tables differ by source: dnoticias.pt puts it as the eighth most frequent cancer and sixth-deadliest in the country, while SAPO, citing the European Cancer Information System (2024), ranks it ninth in incidence (17.8 new cases per 100,000 people) and sixth in mortality (16.5 deaths per 100,000).

Globally, the disease accounts for 531,318 new cases and 490,786 deaths a year, dnoticias.pt reports. Rádio Comercial adds a projection: surgeon Gil Gonçalves of the Botton-Champalimaud Pancreatic Centre estimates Portugal could see 4,000 to 5,000 new cases a year by 2035, roughly double today’s figure, with diagnoses increasingly appearing in people in their 30s, 40s and 50s for reasons not yet fully explained.

“The signs of pancreatic cancer resemble those of common problems, which is why it is easy to postpone going to the doctor. If they persist, don’t wait,” said Gil Gonçalves, general surgeon and president of the Portuguese Pancreas Association (APP).

Pancreas cancer de pancreas
Photo: UOL

Pancreatic Cancer Offers Few Early Warnings

  • Pancreatic cancer gives few early signals; its symptoms look like ordinary digestive complaints.
  • Persistent unexplained weight loss, yellowing skin or eyes, back pain, or sudden diabetes warrant a doctor’s visit without delay.
  • Only about 15% of patients are candidates for surgery at diagnosis — the one potentially curative option — so timing is everything.

Why Nine Deaths in Ten Diagnoses

The pancreas sits behind the stomach, in front of the spine, and produces digestive enzymes and hormones that regulate energy storage. The most common tumor, pancreatic ductal adenocarcinoma, accounts for more than 90% of cases and is among the most aggressive malignancies, the Portuguese Pancreatic Club explained in its awareness push, which A Voz do Algarve covered.

Survival data frame the gap between stages. The overall five-year survival rate is 13%, rising to as much as 44% when the disease is localized but falling to 3% once it has metastasized, gastroenterologist Alexandra Fernandes told A Voz do Algarve. She chairs the Portuguese Pancreatic Club, a specialist section of the Portuguese Society of Gastroenterology.

“It becomes imperative that the population knows this symptomatology and, if it persists, seeks medical help,” Fernandes said, as dnoticias.pt reported.

European data show geography matters too. The EUROCARE-5 studies, covering diagnoses from 1999 to 2007 and summarized in a 2025 publication, found five-year survival of roughly 10.9% in Croatia and 10.5% in Belgium, but 3% or less in Northern Ireland and Malta.

SAPO reports that Europe is mobilizing: the EUnetCCC network of 31 countries with 234 partners designated the first 30 Comprehensive Cancer Centers in February. Eurolife and equity concerns follow from that: for the 2.7 million people diagnosed with cancer in the EU each year, where they live still shapes their care.

Pancreatic Cancer Could Become Second Deadliest by 2035, Portuguese Experts Warn
Photo: SAPO

Symptoms That Hide in Plain Sight

Notícias ao Minuto, citing the charity Pancreatic Cancer Action, worked through the myths. “Silent killer” is a mislabel: symptoms exist but overlap with ordinary illness — indigestion, lower-back pain, weight loss. The cancer is not always fatal: if caught before spread and the patient can tolerate surgery, the tumor can be removed.

It affects men and women almost equally, at a lifetime risk of about 1 in 73 for men and 1 in 74 for women. And though the average age at diagnosis is 72, younger people are diagnosed too.

The main warning signs include unexplained weight loss, jaundice (yellowing skin or eyes), abdominal pain radiating to the back, loss of appetite, diarrhea, nausea, and new-onset or worsening diabetes. When these persist, a CT scan (computed tomography) can establish the diagnosis, dnoticias.pt reported.

Measure Figure Source
Portuguese diagnoses per year 2,191 dnoticias.pt citing GLOBOCAN 2024
Portuguese deaths per year 2,051 dnoticias.pt citing GLOBOCAN 2024
Projected Portuguese cases by 2035 4,000–5,000/year Rádio Comercial
Five-year survival, localized up to 44% A Voz do Algarve
Five-year survival, metastatic 3% A Voz do Algarve

Where Treatment Is Moving

UOL’s reporting describes the therapeutic picture. For borderline or locally advanced tumors, chemotherapy before surgery can shrink disease and raise the odds of complete removal; after surgery it lowers recurrence risk. Regimens include FOLFIRINOX for fit patients, and, for metastatic disease, FOLFIRINOX, NALIRIFOX, or gemcitabine combined with nab-paclitaxel — not cures for most, but options that extend survival and ease symptoms, according to UOL.

Precision medicine adds a second lever. Genetic testing can identify tumor mutations such as BRCA1 and BRCA2, which sensitize some cancers to platinum-based chemotherapy. Immunotherapy helps a small subgroup whose tumors show high microsatellite instability (MSI-H) or DNA-repair deficiency (dMMR).

UOL also reports work on the KRAS gene — mutated in more than 90% of pancreatic adenocarcinomas — where new drugs target the G12D variant, alongside personalized vaccines and liquid biopsies in investigation.

Pancreatic Cancer Could Become Second Deadliest by 2035, Portuguese Experts Warn
Photo: Notícias ao Minuto

Surgery itself has become safer and more precise, allowing more patients into potentially curative care; in specialized centers, operative mortality of 3% to 3.5% is achievable even in complex operations, Rádio Comercial reported.

“These are technically very complex interventions, which require highly specialized teams and surgical experience.”

The Research Funding Deficit

Fernandes draws a hard line on investment: less than 2% of all European cancer research funding goes to pancreatic cancer, dnoticias.pt reported. She is calling for more targeted money toward early-diagnosis methods and personalized therapies.

The awareness infrastructure is expanding meanwhile. Europacolon Portugal and the APP launched the “Pancreatic Cancer: Breaking the Silence” campaign, running through November 28, with video Q&As from five specialists between November 17 and 21 — covering warning signs (Dr. Pedro Reis Pereira, ULS São João), treatment changes, surgery, the diabetes link (endocrinologist Dr. Miguel Vasques), and research.

“Whoever receives this diagnosis often feels they are alone, and so do those who care for them,” Vítor Neves, president of Europacolon Portugal, said in the launch statement carried by dnoticias.pt.

Gonçalves’s role at the Lisbon centre extends beyond the operating table. At the Champalimaud Foundation, where the Botton-Champalimaud Pancreatic Centre is based, he serves as Deputy Chair of Surgical Oncology, a position that places him among the leadership of the team treating the disease he now warns about.

His public outreach also crosses tumour types: on November 18, 2025, he was listed among the speakers at the Foundation’s free public event “Let’s talk about Colorectal Cancer,” which aimed to promote health literacy and prevention of another of Portugal’s leading causes of cancer death.

The event, open to the public and conducted in Portuguese, brought together surgeons, researchers and patient advocates — including Europacolon Portugal’s Vítor Neves, whose organisation features in the pancreatic campaign as well.

Surveillance Urged for High-Risk Individuals

  • People with a family history or hereditary risk should discuss surveillance directly with their doctor; UOL reports identifying these patients is a key early-detection route.
  • Surgery is only for patients in sufficiently good health and without tumor spread; eligibility must be assessed by a specialized multidisciplinary team.

The last dated anchor on the horizon: if projections hold, 2035 is when pancreatic cancer is forecast to overtake all but one other cancer as a cause of death in Portugal and worldwide.

Pancreatic Cancer Could Become Second Deadliest by 2035, Portuguese Experts Warn
Photo: Rádio Comercial

References

  • dnoticias.pt — World Pancreatic Cancer Day, November 19, 2026
  • A Voz do Algarve — “Especialistas alertam para aumento contínuo da incidência do Cancro do Pâncreas”
  • SAPO — “Cancro do pâncreas, prioridade de saúde pública em Portugal e na Europa”
  • UOL — “Por que é tão difícil perceber a doença no início?”
  • Rádio Comercial — “Casos de cancro do pâncreas podem duplicar em Portugal até 2035”
  • Notícias ao Minuto — “Cancro do pâncreas. Mitos e verdades sobre este assassino silencioso”

Photo of author

Health Desk

Health Desk at Archyde.

Arsenal Women 0-2 Lyon Women: Gunners’ Automatic UCL Qualification Chances Suffer Heavy Blow

116 Villagers Trained to Fight Veld Fires, Protect Zimbabwe’s Driefontein Grasslands